Remove Biopharma Remove Leads Remove Side effects
article thumbnail

Merck’s $1.3B Imago Buyout Brings Blood Cancer Drug to Rival BMS, Incyte & GSK

MedCity News

Merck is acquiring Imago BioSciences, a clinical-stage biotech whose lead drug is in development for myelofibrosis and other blood cancers. The deal gives the pharmaceutical giant a small molecule that could provide an alternative to a class of drugs that introduce dangerous side effects.

article thumbnail

CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug

MedCity News

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Liver injuries prompt clinical hold on Sanofi BTK drug

pharmaphorum

billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. All the BTK inhibitors are designed to be able to cross the blood brain barrier and enter the central nervous system, dampening down the autoimmune response that leads to neuronal damage in MS.

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology. Value-based delivery models encourage providers to target costs, quality, and health outcomes.

article thumbnail

Santhera seeks speedy FDA review of Duchenne drug vamorolone

pharmaphorum

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.

FDA 98
article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Can you share an update on the clinical trial for your lead candidate? Hoppin served as lead director of Noria as the two organisations were sold to Bayer Healthcare in June of 2021.

article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

In recent years, the biopharma market has become progressively complex. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors.